Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
04 déc. 2023 08h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
20 nov. 2023 08h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 09h00 HE
|
Atossa Therapeutics, Inc.
Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023...
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
09 nov. 2023 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
18 sept. 2023 08h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 08h30 HE
|
Atossa Therapeutics, Inc.
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver...
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
08 août 2023 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in...
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
20 juil. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
13 juil. 2023 16h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
10 juil. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...